title: [New clinical data with metformin therapy in patients with diabetes mellitus].
abstract: Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.
authors.affiliation: Bajcsy-Zsilinszky Kórház III. Belgyógyászati Osztály Budapest Maglódi út 89-91. 1106. gyjermendy@mail.datanet.hu
authors.forename: György
authors.initials: G
authors.lastname: Jermendy
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D048909:Diabetes Complications / Q000097:blood / Q000453:epidemiology* / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D006333:Heart Failure / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015994:Incidence; D007328:Insulin / Q000008:administration & dosage; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D009765:Obesity / Q000150:complications* / Q000503:physiopathology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin